Acalabrutinib is an anti-cancer medicine (tyrosine kinase inhibitor) showing promise in early studies. Its potential mechanism of action (MoA) is poorly understood. If understood better, more anti-cancer drugs can be rationalized against COVID-19. MoA elements include genes, and pathways that may explain the MoA of the drug in particularly ameliorating cytokine storm-related features in COVID-19. … Read More
Explore immune checkpoint blockade (PD-1, CTLA-4) in cancer immunotherapy with Biovista Vizit. Explore the live graph.
Association of microbiome organisms to Regulatory T Cell function in cancer and inflammation. Explore the live graph.